iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Hits New 52-Week High – Still a Buy?

Posted by Paula Ricardo on May 27th, 2026

Shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $92.42 and last traded at $92.42, with a volume of 11949 shares trading hands. The stock had previously closed at $91.19.

iShares U.S. Pharmaceuticals ETF Stock Up 0.7%

The firm has a market capitalization of $992.09 million, a price-to-earnings ratio of 17.75 and a beta of 0.49. The firm’s 50 day moving average is $87.26 and its 200 day moving average is $86.44.

Institutional Trading of iShares U.S. Pharmaceuticals ETF

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. EFG International AG acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at approximately $38,000. O Shaughnessy Asset Management LLC raised its holdings in shares of iShares U.S. Pharmaceuticals ETF by 35.0% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 463 shares of the company’s stock valued at $39,000 after acquiring an additional 120 shares during the period. Assetmark Inc. raised its holdings in shares of iShares U.S. Pharmaceuticals ETF by 203.9% during the fourth quarter. Assetmark Inc. now owns 465 shares of the company’s stock valued at $39,000 after acquiring an additional 312 shares during the period. Blueline Advisors LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at approximately $41,000. Finally, Accent Capital Management LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at approximately $42,000.

iShares U.S. Pharmaceuticals ETF Company Profile

(Get Free Report)

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.